Navigation Links
New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures
Date:12/9/2008

>

Keppra XR(TM) should be gradually withdrawn to minimize the potential of increased seizure frequency.

Dosing must be individualized according to the patient's renal function status. In patients with end-stage renal disease on dialysis, it is recommended that immediate-release Keppra(R) be used instead of Keppra XR(TM).

For full prescribing information, please see www.KeppraXR.com.

In order to ensure patient access to this valuable medication in the U.S., UCB is initiating a co-pay support program. For more information, contact U.S. UCB Medical Information at 1-866-822-0068 (press 9).

About Epilepsy

Epilepsy is a chronic neurological disorder affecting approximately three million people in the U.S. -- making it more common than multiple sclerosis and Parkinson's disease combined. It is caused by abnormal, excessive electrical discharges of the nerve cells, or neurons, in the brain. Epilepsy is characterized by a tendency to have recurrent seizures and defined by two or more unprovoked seizures. There are many different seizure types and epileptic syndromes. Forty percent of patients taking only one AED continue to experience seizures, and approximately 30% of patients taking adjunctive therapy continue to experience seizures. This highlights the ongoing need for the development of new AEDs. For more information about epilepsy, visit www.epilepsyfoundation.org, www.epilepsy.com, or www.epilepsyadvocate.com.

    Further information
    Andrea Levin
    Public Relations Manager, CNS, UCB
    Phone: 770-970-8352
    Email: andrea.levin@ucb-group.com
'/>"/>
SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
2. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
3. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
4. New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting
5. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
6. SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
7. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
8. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
9. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
10. Opportunities to Highlight Type 1 Diabetes in November
11. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today ... diagnostic platform during a special event at the company,s ... , on September 5, 2014. The event, which will ... the ApolloDx website, www.apollodx.com .    ... testing," said Jared Bauer , Co-Founder and Managing ...
(Date:8/20/2014)... 20, 2014 Trovagene, Inc. (NASDAQ:   TROV), ... results from two clinical studies will be presented at ... urine-based diagnostic test for the detection of high risk ... scheduled to take place in Seattle ... . Additionally, a new U.S. patent was issued earlier ...
(Date:8/20/2014)... England , August 20, 2014 ... be Conducted in the US  KalVista Pharmaceuticals ... macular edema (DME), today announces that it has begun ... novel plasma kallikrein inhibitor, KVD001, for the treatment of ... Sun of the Beetham Eye Institute, Joslin Diabetes Center; ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Sept. 18 A long-term study found,that a ... with life-threatening,diseases, such as leukemia and lymphoma, results ... males are likely to recover,from these changes over ... In addition, neither male nor female long-term cancer,survivors ...
... Bacterial Infection and May ... Bacterial Infections, BOSTON, Sept. 18 Paratek ... of the Company,s,Multiple Adaptation Response (MAR) inhibitor program. ... controlling virulence and antibiotic,resistance. Paratek has shown that ...
Cached Medicine Technology:Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 2Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 3Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 4Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 3Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:8/20/2014)... Aug. 20, 2014 (HealthDay News) -- Pigs, hearts transplanted ... is twice as long as previously achieved, researchers report. ... ways to use animal organs to shorten transplant waiting ... genetically engineered piglets into baboons, abdomens. The genetic engineering ... response are what enabled the hearts to survive for ...
(Date:8/20/2014)... Thompson HealthDay Reporter WEDNESDAY, ... older women avoid a condition that causes a life-threatening irregular ... had a 10 percent lower risk of developing atrial fibrillation, ... the Aug. 20 issue of the Journal of the ... against the heart rhythm disorder even if they were obese, ...
(Date:8/20/2014)... New York, NY (PRWEB) August 20, 2014 ... and architecture firm Perkins Eastman is pleased ... and design services in China and ... internationally recognized Principal Richard Sprow AIA has ... continue his 40-year career in healthcare planning and design ...
(Date:8/20/2014)... A common approach to treating kidney failure by removing ... chances for people who suddenly developed the condition, in ... Pittsburgh School of Medicine. , Their findings, published online ... hemodialysis, an aggressive method that is standardly used for ... definitive benefit to the patient. , "Our findings question ...
(Date:8/20/2014)... New York (PRWEB) August 20, 2014 ... the use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) ... notes that two U.S. Senators from New York are ... seek a recall of the devices. In a letter ... both Democrats, also implored the agency to seriously consider ...
Breaking Medicine News(10 mins):Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 3Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4
... and candidates faster, brings unprecedented functionality and ease of use to ... ... -- Dayak, the leading online recruiting marketplace used by ... more efficiently, today launched a new version of its user interface ...
... are trying to economize by choosing cheaper shipping methods , ... ... www.medisave.net ), a leading global medical equipment merchant with ... today announced that despite the global credit crunch, global sales have ...
... Indication this Year; Data Demonstrate High,Durable Response Rates ... a Rituximab-Containing Regimen, FRAZER, Pa., Nov. 3 ... U.S. Food and Drug Administration (FDA) has,approved TREANDA(R) ... with indolent B-cell non-Hodgkin,s lymphoma (NHL),that has progressed ...
... of Allergy and Infectious Diseases (NIAID) scientist Theodore E. ... with areas of brain tissue swelling in people infected ... form around dead, calcified cysts that result when larvae ... brain. The illness caused by T. solium ...
... provider team up to market ... final expense planning, ... Corporation International (NYSE: SCI ) have formed a,unique partnership through ... Final Expense insurance., This is an extraordinary combination of services ...
... 2008, JUPITER, Fla., Nov. 3 From November 15 -17, ... promote,National Smoke Out Day, November 20, and to promote her new ... -- MISS AMERICA 2008 KIRSTEN HAGLUND, WILL BE AVAILABLE ... NOVEMBER 15-17 TO PROMOTE SAVING LIVES, AND ...
Cached Medicine News:Health News:Dayak Makes Hiring Even Easier, Unveils New Version Of Web Interface For Employers 2Health News:Dayak Makes Hiring Even Easier, Unveils New Version Of Web Interface For Employers 3Health News:Despite Credit Crunch, Medisave Sees Strong Sales Increase in 2008 2Health News:Despite Credit Crunch, Medisave Sees Strong Sales Increase in 2008 3Health News:Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 2Health News:Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 3Health News:Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 4Health News:Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 5Health News:SLAICO and SCI Form Partnership 2
Replacement bulb for Vibratome light system....
The V-Block adapter is designed to allow round posts to be placed in the Vibratome vice....
This is a perfect tool for retrieving free floating sections from the Vibratome bath....
... Works includes everything from the care ... fuse, Spare Fluorescent Bulb, additional Vibratome ... Blocks, and a Specimen Tray. ... stage, 1/2" speciment mounts, replacement rotating ...
Medicine Products: